GHRPs are a small family of peptides acting at the pituitary and the hypothalamus to release Growth hormone (GH) through the activation of a specific, G protein-coupled receptor.
They were discovered 20 years ago as synthetic metenkephalin- derived oligopeptides (Synthetic tissue derived amino acids). Although it has no structural homology with Growth Hormone Releasing Hormone (GHRH), in clinical studies GHRP-2 demonstrated action on the pituitary to release Human Growth Hormone (HGH). Similar results were effective when GHRP-2 was administered sublingual. Clinical studies showed the most potent GHRP being the hexapeptide GHRP-2.
Growth Hormone Releasing Peptide 2(GHRP2) substantially stimulates the pituitary gland's increased natural production of the body's own endogenous human growth hormone (HGH). This therapy consists of daily periodic sub-lingual dosing. Growth Hormone releasing peptide 2, GHRP2 has shown on it's own to robustly increase IGF-1 levels, and even greater results occurred when used with Growth Hormone Releasing Hormone (GHRH) to which also stimulates the pituitary gland to produce increased natural secretion of human growth hormone. This also boosts the hypothalamus function as well.
The results of the clinical studies published in the Journal of Endocrinology and Metabolism in 1997 for GHRP2 - showed that a medically supervised, prescribed and administered therapy increased growth hormone levels in adults and children, who have growth hormone deficiency.
The increase in the body's growth hormone via elevated IGF-1 levels produced by the pituitary gland in response to GHRP2 therapy -- has an anabolic effect on the tissues of the body and other benefits identified below.
A: This can be used alone or as an adjunct to HGH therapy. Both methods will yield robust results. The synergy of using GHRP2 with injectable growth hormone is that it allows your own natural production to remain and rebuild along with the use of injectable growth hormone. GHRP2 works greatly on it's own as well.
A: Growth hormone has a brief half life and is rendered ineffective when orally applied, swallowed and passed into the gastric tract. Then it must pass through the liver when applied orally. This is why HGH is effectively administered through subcutaneous injections. Conversely, GHRP2 oral mucosal medicine delivery i.e.: sublingual/ intranasal as demonstrated in clinical studies, is an effective alternative method of systemic medicine /supplement delivery that offers not only impressive results -- but several advantages over both injectable and enteral methods.
Because the oral mucosa is highly vascularised, medi-suppliments that are absorbed through the oral mucosa directly enter the systemic circulation, bypassing the gastrointestinal tract and first pass metabolism in the liver. For some supplements and drugs, this results in rapid onset of action via a more comfortable and convenient delivery route than the intravenous route. Not all medications, however, can be administered through the oral mucosa because of the characteristics of the oral mucosa and the physicochemical properties of the supplement.
GHRP2 can be delivered sublingual and is the preferred method of application -- and in a peer reviewed clinical study from the Department of Pediatrics at the University of Arkansas for Medical Sciences, published in the Journal of Endocrinology and Metabolism in 1995, "All 15 children had a significant GH response to 15 pg/kg dose. The intranasal /mucosa delivery was well tolerated."
To receive more information on GHRP2 Therapy, please fill out the form, or Call 786-228-9558.
GHRP2 growth hormone releasing peptide2 therapy is considered one of a few medical means of reversing the effects of aging in adults deficient in growth hormone. This is because of the benefits resulting from the increased stimulation and secretion of human growth hormone by the pituitary gland hypothalamus,axis HPA.